JAK2 inhibitors in myelofibrosis.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

JAK2 inhibitors in myelofibrosis.

Clinical advances in hematology & oncology : H&O - 1 Nov 2011

Pardanani Animesh

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Janus Kinase 2
Share to Nitriles
Share to Primary Myelofibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyrimidines

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 22252617

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 inhibitors in myelofibrosis.PMID 22252617Read ↗

JAK2 inhibitors and myeloproliferative neoplasms.Semantic proximity Read ↗

How many JAK inhibitors in myelofibrosis?Semantic proximity Read ↗

Management of Myelofibrosis: from Diagnosis to New Target Therapies.Semantic proximity Read ↗

[JAK2 mutation in myeloproliferative disorders].Semantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

Emerging targeted therapies in myelofibrosis.Semantic proximity Read ↗

Janus activated kinase inhibition in myelofibrosis.Semantic proximity Read ↗

JAK2: implications for diagnosis and classification of myeloproliferative disorders.Semantic proximity Read ↗

<i>JAK2</i>Mutations in Myeloproliferative DisordersSemantic proximity Read ↗

Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.Semantic proximity Read ↗

Investigational Janus kinase inhibitors in development for myelofibrosis.Semantic proximity Read ↗

A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.